Logan Capital Management’s Edwards Lifesciences EW Stock Holding History

Logan Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$290K	Buy	+3,621	New	+$299K	0.01%	263

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Logan Capital Management's EW Position: Q1 2026 in Review

Logan Capital Management sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 3,621 shares — an estimated $299K sold.

Logan Capital Management first reported a position in EW in Q2 2013 and held it in 32 quarters. The position peaked at $15.2M in Q2 2013. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Logan Capital Management reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
Logan Capital Management sold 3,621 Edwards Lifesciences shares in Q1 2026, an estimated $299K.
Logan Capital Management first reported a position in Edwards Lifesciences in Q2 2013 and held it in 32 quarters.
Logan Capital Management's Edwards Lifesciences position peaked at $15.2M in Q2 2013.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Logan Capital Management's 13F filing for Q1 2026, filed 8 May 2026.